NeoDynamics announces the preliminary subscription price for the exercise of warrants of series TO3, with the exercise period commencing today.

NeoDynamics conducted a rights issue of units ("the Rights Issue") in August 2023. Each unit issued in the Rights Issue consisted of six (6) shares and five (5) free-of-charge warrants, including two (2) series TO2 warrants and three (3) series TO3 warrants, where each subscription option entitles the holder to subscribe for a new share. Upon full exercise of all series TO3 warrants, NeoDynamics will receive approximately 5.0 million SEK before transaction costs.

The subscription price for the warrants was previously determined to be a subscription price corresponding to 70 percent of the volume-weighted average price during the period from February 1, 2024, to February 15, 2024, however, not less than the current share's quota value rounded up to two decimal places, which amounted to 0.02 SEK per share, and not more than 0.15 SEK.

As a result of the recently completed share consolidation, a recalculation of both the range, subscription price, and the number of series TO3 warrants required to subscribe for new shares was carried out. After the consolidation, the total number of shares in the Company decreased from 724,595,100 shares to 7,245,951 shares. The shares have a quota value of 1.725 SEK per share. The range for the subscription price became at least the current share's quota value rounded up to two decimal places, amounting to 1.73 SEK per share, and at most 15 SEK per share. Seventy percent of the volume-weighted average price during the measurement period fell below 1.73 SEK, and thus, the subscription price is set at 1.73 SEK. It is noted that the prevailing market share price is below this redemption price. As a consequence of the consolidation, 100 warrants of series TO3 are required to subscribe for 1 new share.

Summary of instructions and important dates

Holders of Warrants who wish to exercise these to subscribe for shares shall give notice regarding such exercise at latest on March 1, 2024. Warrants that have not been exercised on or before March 1, 2024, expire without value. Holders who do not wish to exercise their Warrants may sell them. Trading with Warrants is ongoing up to and including February 28, 2024.

Detailed information and instructions for subscription

Exercise of nominee-registered Warrants

Holders of Warrants who have their holdings nominee-registered (holdings in securities custody services, investment savings accounts (ISK) or endowment insurances) must notify the exercise of Warrants by contacting their respective nominee and follow the nominee's instructions regarding subscription and payment. This should take place well before March 1, 2024, as different nominees have different processing times.

Exercise of directly registered Warrants

Holders of Warrants who have their holdings directly registered (holdings on a VP account) must notify the exercise of Warrants by filling in and submitting an application form for the exercise, so that the application form is received by the issuing agent, Nordic Issuing, no later than March 1, 2024.

The application form is available on the Company's, the issuing agent's and Redeye AB's respective websites (www.neodynamics.com, www.nordic-issuing.se, www.redeye.se). Please note that payment for the new shares must be received by Nordic Issuing no later than March 1, 2024, in accordance with the instructions on the application form.

Trading in TO3

Holders who do not wish to exercise their Warrants may sell them on Nasdaq First North. The Warrants are traded up to and including February 28, 2024, under the short name NEOD TO3 and with ISIN code SE0020552503. Warrants that are not exercised on March 1, 2024, at the latest will expire without value.

Outcome and delivery of new shares

The outcome of the exercise of Warrants will be published via a press release on or around March 5, 2024. Shares that have been subscribed and paid for may be registered on the subscriber's securities depository as interim shares (IA) until registration of the issue has been completed with the Swedish Companies Registration Office, whereupon the interim shares automatically will be converted into shares in NeoDynamics.

Increase in the number of shares and share capital

Upon full utilization of all 289,219,665 Warrants series TO3, the share capital will increase by a maximum of SEK 4,989,038.10 to SEK 17,488,303.58 SEK through the issuance of maximum of 2,892,196 new shares, resulting in that the total number of shares in the Company will increase from 7,245,951 to 10,138,147. Upon full utilization of all Warrants series TO3, the dilution of the shares amounts to approximately 28.5 percent.

The Upcoming Rights Issue

On February 2, 2024, the Company decided on a rights issue of shares (“The Upcoming Rights Issue”). In accordance with the terms of the Warrants, exercising the Warrants does not entitle participation in The Upcoming Rights Issue.

The Upcoming Rights Issue will result in a recalculation of the terms of the Warrants. Such recalculation may only occur after the end of the subscription period and will apply to the exercised Warrants.

Full terms of the Warrants

The full terms of the Warrants are available on the Company's website, www.neodynamics.com.

Advisers

Redeye AB is a financial advisor in connection with the Rights Issue. Advokatfirman Lindahl KB acts as legal advisor to NeoDynamics in connection with the Rights Issue. Nordic Issuing AB acts as the issuing agent in connection with the Rights Issue.

For further information, please contact:

Anna Eriksrud, CEO NeoDynamics AB, phone 0708 444 966 or e-mail anna.eriksrud@neodynamics.com

Aaron Wong, CFO NeoDynamics AB, phone 0735 972 011 or e-mail aaron.wong@neodynamics.com

About NeoDynamics

NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. NeoNavia® is CE approved, and in September 2022, received a 510k approval from the FDA. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in Europe and launches in USA during 2023. NeoDynamic’s shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company’s Certified Adviser is Redeye AB.

About NeoNavia®

NeoNavia® is the trade name for the complete biopsy system intended for use in ultrasound-guided sampling. NeoNavia® consists of a base unit, a hand unit, and three types of biopsy needles. The pulse technology drives the respective needle type, which facilitates needle insertion and placement in the suspected tumor. The system is designed to offer physicians and patients precise and robust tissue sampling for accurate diagnosis and individualized treatment.

About the pulse technology

The patented pulse technology is based on a pneumatically driven mechanism that enables high precision and control when inserting and positioning the biopsy needle, regardless of tissue type. The pneumatic drive unit that generates pulses is located in a hand-held instrument. With power from the base unit, the hand-held driver accelerates the biopsy needle with great control, even over short distances, enabling a distinct step-by-step insertion without affecting the surrounding tissue. This enables good access and flexibility in sampling, even in tiny and tricky localized tumors.

For more information, please visit Neodynamics.com.

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in NeoDynamics. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in NeoDynamics has only been made through the prospectus published by NeoDynamics on July 31, 2023, and through the supplement prospectuses published by NeoDynamics on August 11, 2023. The prospectuses have been approved and registered by the Swedish Financial Supervisory Authority and have been published on the Company’s website, www.neodynamics.com.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.